NEOGENOMICS INC
For the period ended Dec 31, 2024. Filed Apr 8, 2025.
View on SEC.govAbout this filing
What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.
Dec 31, 2024 · Filed Apr 8, 2025
Contents
Cover page
Show cover page
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
(Amendment No. )
Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐
| Check the appropriate box: | |
|---|---|
| ☐ | Preliminary Proxy Statement |
| ☐ | Confidential, For Use of the Commission Only (As Permitted by Rule 14a-6(e)(2)) |
| ☒ | Definitive Proxy Statement |
| ☐ | Definitive Additional Materials |
| ☐ | Soliciting Material under Rule 14a-12 |
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check all boxes that apply):
| ☒ | No fee required. |
|---|---|
| ☐ | Fee paid previously with preliminary materials. |
| ☐ | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. |
April 8, 2025
9490 NeoGenomics Way
Fort Myers, Florida 33912
Fellow Stockholders,
On behalf of the Board of Directors, it is my pleasure to invite you to attend our 2025 Annual Meeting of Stockholders of NeoGenomics, Inc., which will be held on Thursday, May 22, 2025, at 10:00 a.m., Eastern Time (the "2025 Annual Meeting"). The 2025 Annual Meeting will be a completely virtual meeting conducted via live webcast.
Details regarding the 2025 Annual Meeting and the business to be conducted are described in the accompanying Proxy Statement. In addition to considering the matters described in the Proxy Statement, we will report on matters of interest to our stockholders.
We are pleased to inform you that instead of a paper or electronic copy of our proxy materials, most of our stockholders will be mailed a Notice of Internet Availability of Proxy Materials (“Notice of Internet Availability”) on or about April 8, 2025. The Notice of Internet Availability contains instructions on how to access proxy materials and how to submit your proxy over the Internet. The Notice of Internet Availability also contains instructions on how to request a paper copy of our proxy materials, if desired. All stockholders who do not receive a Notice of Internet Availability, or who have not consented to receive their proxy materials electronically by email, will be mailed a paper copy of the proxy materials. Furnishing proxy materials over the Internet allows us to provide our stockholders with the information they need in a timely manner, while reducing the environmental impact and lowering the costs of printing and distributing our proxy materials.
Your vote is important to us. Please act as soon as possible to vote your shares. It is important that your shares be represented at the 2025 Annual Meeting whether or not you plan to attend the live webcast of the 2025 Annual Meeting. Please vote electronically over the Internet, by telephone, or, if you receive a paper copy of the proxy card by mail, by returning your signed proxy card in the envelope provided. You may also vote your shares online during the 2025 Annual Meeting. Instructions on how to vote while participating at the 2025 Annual Meeting live via the Internet are posted at www.virtualshareholdermeeting.com/NEO2025.
On behalf of the Board of Directors and management, we thank you for your continued support and confidence in NeoGenomics, Inc.
Sincerely,
Lynn A. Tetrault
Non-Executive Chair of the Board of Directors
NOTICE OF 2025 ANNUAL MEETING OF STOCKHOLDERS
NOTICE IS HEREBY GIVEN that the Annual Meeting of Stockholders of NeoGenomics, Inc., will be held on Thursday, May 22, 2025, at 10:00 a.m., Eastern Time (the "2025 Annual Meeting"). The 2025 Annual Meeting will be a completely virtual meeting, which will be conducted via live webcast. You will be able to attend the 2025 Annual Meeting online and submit your questions during the 2025 Annual Meeting by visiting www.virtualshareholdermeeting.com/NEO2025. For instructions on how to attend and vote your shares at the 2025 Annual Meeting, see the information in the accompanying Proxy Statement.
Items of Business:
To elect nine directors from the nominees named in the attached Proxy Statement.
To approve, on a non-binding advisory basis, executive compensation.
To recommend, on a non-binding advisory basis, the frequency of future advisory votes on the compensation paid to our named executive officers.
To approve the First Amendment of the NeoGenomics, Inc. 2023 Equity Incentive Plan.
To ratify the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the year ending December 31, 2025.
To consider any other business properly brought before the 2025 Annual Meeting.
Record Date:
You can vote if you were a stockholder of record as of the close of business on March 24, 2025.
Proxy Voting:
| By Mail | By Phone | By Internet |
|---|
It is important that your shares be represented at the 2025 Annual Meeting regardless of the number of shares you hold. Whether or not you expect to virtually attend, please complete, date, sign and return the accompanying proxy card in the enclosed envelope or use the telephone or Internet method of voting as described on your proxy card to ensure the presence of a quorum at the meeting. Even if you have voted by proxy and you virtually attend the meeting, you may, if you prefer, revoke your proxy and vote your shares virtually.
By Order of the Board of Directors
Alicia C. Olivo
EVP, General Counsel & Business Development
Important notice regarding the availability of proxy materials for the 2025 Annual Meeting of Stockholders to be held on Thursday, May 22, 2025. Our 2025 Proxy Statement and 2024 Annual Report to Stockholders are available at www.proxyvote.com.
TABLE OF CONTENTS
| PROXY OVERVIEW | 1 |
|---|---|
| CORPORATE GOVERNANCE | 3 |
| Information Regarding Meetings and Committees of the Board | 9 |
| PROPOSAL 1—ELECTION OF DIRECTORS | 13 |
| Information as to Nominees and Other Directors | 13 |
| Vote Required for Approval | 21 |
| Board Recommendation | 21 |
| PROPOSAL 2—ADVISORY VOTE ON EXECUTIVE COMPENSATION | 22 |
| Vote Required for Approval | 22 |
| Board Recommendation | 22 |
| PROPOSAL 3—ADVISORY VOTE ON THE FREQUENCY OF FUTURE ADVISORY VOTES ON EXECUTIVE COMPENSATION | 23 |
| Vote Required for Approval | 23 |
| Board Recommendation | 23 |
| PROPOSAL 4—FIRST AMENDMENT OF THE 2023 EQUITY INCENTIVE PLAN | 24 |
| Description of the Plan | 24 |
| Vote Required for Approval | 29 |
| Board Recommendation | 29 |
| PROPOSAL 5—RATIFICATION OF APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM | 30 |
| Independent Registered Public Accounting Firm Fees | 30 |
| Audit and Finance Committee Report | 31 |
| Vote Required for Approval | 31 |
| Board Recommendation | 31 |
| EXECUTIVE OFFICERS | 32 |
| COMPENSATION OF INDEPENDENT DIRECTORS | 34 |
| EXECUTIVE COMPENSATION | 36 |
| Compensation Discussion and Analysis | 36 |
| Culture and Compensation Committee Report | 53 |
| Executive Compensation Tables | 54 |
| Summary Compensation Table | 54 |
| Grants of Plan-Based Awards | 56 |
| Narrative Disclosure to the Summary Compensation Table and the Grants of Plan Awards Table | 57 |
| Options Exercised and Stock Vested | 59 |
| Outstanding Equity Awards on December 31, 2024 | 60 |
|---|---|
| Employment Agreements and Potential Payments Upon Termination or Change in Control | 62 |
| Chief Executive Officer Pay Ratio | 65 |
| Pay Versus Performance | 66 |
| Equity Compensation Plan Information | 70 |
| SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT | 71 |
| FUTURE STOCKHOLDER PROPOSALS | 73 |
| TRANSACTIONS WITH RELATED PERSONS | 74 |
| OTHER MATTERS | 75 |
| IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE 2025 ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON MAY 22, 2025 | 76 |
| QUESTIONS AND ANSWERS ABOUT THE 2025 ANNUAL MEETING | 77 |
| ANNEX A: FIRST AMENDMENT OF THE NEOGENOMICS, INC. 2023 EQUITY INCENTIVE PLAN | A-1 |
Index of Frequently Requested Information
| Auditor Fees | 30 |
|---|---|
| Board Leadership Structure | 5 |
| CEO Pay Ratio | 65 |
| Clawback Policy | 24 |
| Compensation Design | 39 |
| Culture and Compensation Governance | 41 |
| Director Attendance | 9 |
| Director Independence | 6 |
| Director Qualifications | 13 |
| Managing Compensation Related Risks | 43 |
| Nominee Biographies | 13 |
| Pay Versus Performance | 66 |
| Risk Oversight | 6 |
| Stockholder Engagement | 44 |
| Stockholder Engagement on the 2024 Say-on-Pay Vote | 44 |
| Summary Compensation Table | 54 |
| Use of an Independent Advisor | 42 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.